देश: ऑस्ट्रिया
भाषा: अंग्रेज़ी
स्रोत: HMA (Heads of Medicines Agencies)
marbofloxacin 80 mg
Emdoka bvba
QJ01MA
Tablet
Fluoroquinolones
Dogs Non Food
2013-06-26
Issued: September 2013 AN: 00540/2012 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare flavour 80mg tablets for dogs (UK and IE) Marbocare F 80mg tablets for dogs (FR) Odimar 80mg tablets for dogs (BE, LU, NL) Marbofloxacin WDT 80mg flavoured tablets for dogs (AT, DE) Marbofloxacino Emdoka 80mg tablets for dogs (ES) Marbofloxacina Emdoka 80mg tablets for dogs (PT) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION EACH TABLET CONTAINS: ACTIVE SUBSTANCE: Marbofloxacin 80.0mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Beige brown spotted oblong tablets, deep score line upper side, score line lower side. The tablet can be divided into halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Marbofloxacin is indicated in the treatment of the following infections caused by susceptible strains of organisms (See section 5.1); Skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis). Urinary tract infections (UTI) associated or not with prostatitis or epididymitis. Respiratory tract infections. Issued: September 2013 AN: 00540/2012 Page 2 of 6 4.3 CONTRAINDICATIONS Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period. Do not use in cats. For the treatment of this species, a 5 mg tablet is available. Do not use in animals with known hyp पूरा दस्तावेज़ पढ़ें